For providers
Interpreting results

How to read your patient's test results

Oncotype DX Breast Recurrence Score® test results are easy and straightforward to interpret. Explore the report below to learn more. 
A doctor and patient reviewing test results on a tablet.

Explore the report

The results report is broken down into three sections, each of which give you key insights into your patient’s condition based on their personal tumor biology. It reveals the likelihood of distant recurrence, and how likely they are to benefit from chemotherapy.1-6,9,12
Node-negative
An illustrated card showing a test score of 20.

Score

The Recurrence Score result is based on the quantitative analysis of the expression of 21 genes within the patient’s tumor sample, and ranges from 0-100. The lower the score, the lower the likelihood of your patient's cancer returning somewhere else in their body if they take endocrine therapy alone and the higher the score, the higher the likelihood of your patient's cancer returning. As their score increases, the magnitude of chemotherapy benefit also increases.1-3,5,9,13
An illustrated card showing a 7% distance recurrence risk at 10 years.

Prognosis

This is your patient’s individualized risk of distant recurrence when treated with endocrine therapy alone.1,5,9,13*
An illustrated card showing group average absolute chemotherapy benefit.

Prediction

The Group Average Absolute Chemotherapy Benefit shows the average reduction in distant recurrence risk when chemotherapy is added to endocrine therapy, for all ages within the specified Recurrence Score range.3,5,9,13*

* This is a sample report of a node-negative patient based on the TAILORx trial.3,5,9,13

Node-negative report sample
A sample report displaying hypothetical test results.
Node-positive
An illustrated card showing a test score of 16.

Score

The Recurrence Score result is based on the quantitative analysis of the expression of 21 genes within the patient’s tumor sample, and ranges from 0-100. The lower the score, the lower the likelihood of your patient's cancer coming back somewhere else in their body if they take endocrine therapy alone and the higher the score, the higher the likelihood of your patient's cancer coming back. As their score increases, the magnitude of chemotherapy benefit also increases.2,4,6
An illustrated card showing a 6% distance recurrence risk at 5 years.

Prognosis

This is your patient’s individualized risk of distant recurrence when treated with endocrine therapy alone. 2,4,6*
An illustrated card showing group average absolute chemotherapy benefit.

Prediction

The Group Average Absolute Chemotherapy Benefit shows the average reduction in distant recurrence risk when chemotherapy is added to endocrine therapy for patients with similar menopausal status within the specified Recurrence Score range4,6*

* This is a sample report for a premenopausal node-positive patient based upon data from RxPONDER.6

Node-positive report sample
A sample report displaying hypothetical test results.

How a report is generated

The Oncotype DX Breast Recurrence Score test analyzes the expression of 21 genes in tumor tissue obtained at the time of core biopsy or surgical excision.1,7
A chart showing a breakdown of the 21 genes included in the Assay.

Gain greater insight with the RSClin® Tool

By integrating the Recurrence Score result with clinical and pathological features, the RSClin Tool offers additional insights to help inform treatment decisions and provide individualized estimates of distant recurrence and absolute chemotherapy benefit, particularly in cases where further clarity is needed.8-11,†
A doctor seated at a desk looking at his laptop.

Ordering a test for your patients is fast and easy

Order tests, access results, and receive updates through our Provider Hub.

Have questions?

Call us at 1 866-662-6897.